Wegovy vs Semasize: Is There a Real Difference? (Same Molecule, Very Different Bill)
No, there is no difference in the medicine itself. Wegovy and Semasize both contain semaglutide. The real differences are price (₹5,660 to ₹16,400 vs from ₹1,800 a month), the device, and the dose ladder. Here is the honest comparison.
ALTRcare Medical Team
Clinical Editorial
If you are weighing Wegovy against Semasize, start with the fact that settles most of the question: they contain the same medicine. Both are semaglutide, a once-weekly injection. Semasize is not a 'similar' molecule or an imitation compound; it is semaglutide made by Alkem, approved by India's drug regulator after a head-to-head Phase 3 trial against the Novo Nordisk original. What genuinely differs is the bill: Wegovy runs ₹5,660 to ₹16,400 a month depending on dose, while Semasize starts near ₹1,800 a month. Over a 9 to 12 month course, that gap is ₹40,000 to ₹1,00,000. The honest comparison below covers the three differences that actually remain.
The evidence: Semasize was tested against the original, not just approved on paper
This is the part most people do not know. India's CDSCO cleared post-patent semaglutide under the Subsequent New Drug pathway, which required completed Phase 3 trials in Indian patients. Alkem's SIZE-DM trial randomized 320 patients between Semasize and the Novo Nordisk original for 24 weeks and demonstrated non-inferiority, with both arms reducing HbA1c by a mean of 2.20 percent. Very few generics anywhere in the world are launched with head-to-head data against the originator. So the question is not whether Semasize is real semaglutide. It is whether the three remaining differences are worth 3 to 8 times the price to you.
The three real differences
| Factor | Wegovy (Novo Nordisk) | Semasize (Alkem) |
|---|---|---|
| Active molecule | Semaglutide | Semaglutide (same) |
| Monthly cost | ₹5,660 to ₹16,400 by dose | From about ₹1,800 |
| Trial evidence | Global STEP program, tens of thousands of participants | Indian Phase 3, head-to-head non-inferiority vs the original |
| Device | FlexTouch pen, decades of device refinement | Indian pen device, newer to market |
| Dose ladder | Full ladder to 2.4 mg guaranteed in stock | High-dose availability still maturing |
| Track record at scale | Years, globally | Months, in India |
When Wegovy is worth paying for
- You specifically need the 2.4 mg maintenance dose and want it guaranteed in stock every month, since the highest doses are where Indian generic availability is still catching up.
- You have been stable on Wegovy for months and the extra cost genuinely does not matter to your budget. There is no clinical need to change something that is working.
- You place high value on the longest possible manufacturer track record and are willing to pay a large premium for it.
When Semasize is the smarter choice
For most Indian patients starting medical weight loss in 2026, the arithmetic is hard to argue with. Weight management with semaglutide is a multi-month journey, and adherence is what drives results. A price that a family can sustain for 9 to 12 months beats a premium brand that gets abandoned in month 3 because the bills piled up. The molecule is identical, the Indian trial evidence is unusually strong for a generic, and the money saved funds the things that actually improve outcomes: doctor follow-ups, a proper diet plan, and consistency. Individual results vary with any semaglutide.
The comparison that actually matters: genuine vs fake
The risky choice in India is not Wegovy vs Semasize. It is a licensed pharmacy product vs the unregulated vials sold on Telegram and Instagram. Both Wegovy and Semasize are safe, genuine options when prescribed by a doctor and bought through a licensed channel. Anything sold without a prescription is not.
Switching between them
Because the molecule is the same, switching from Wegovy to Semasize (or the reverse) is straightforward under a doctor's supervision: the dose carries over directly, with no washout period and no restart from the lowest dose. At ALTRcare, our doctors handle this switch routinely for patients who started on the imported brand and want their monthly costs to come down without changing their medicine.
Key takeaways
- Wegovy and Semasize contain the same molecule: semaglutide. There is no difference in the medicine itself.
- Semasize was proven non-inferior to the Novo Nordisk original in a 320-patient head-to-head Indian trial.
- The real differences are price (3 to 8x), device maturity and high-dose availability.
- Switching between them needs no washout; the dose carries straight over under doctor supervision.
Get a doctor's take on the right brand for you
Take the 2-minute assessment. An ALTRcare doctor reviews your profile and recommends the option that fits your goals and budget.
Frequently asked questions
Is there a big difference between Wegovy and Semasize?
Not in the medicine. Both contain semaglutide, and Semasize demonstrated non-inferiority against the Novo Nordisk original in a head-to-head Indian Phase 3 trial. The differences are price (3 to 8x), the injection device, and high-dose availability.
Is Semasize as effective as Wegovy?
Semasize contains the same molecule at the same weekly dosing principle, and its approval trial showed non-inferiority against the original. As with any semaglutide, individual results vary and depend on dose, adherence and lifestyle support.
Can I switch from Wegovy to Semasize?
Yes, under a doctor's supervision. Because the molecule is identical, your current dose carries over directly with no washout period and no need to restart from 0.25 mg.
Why is Wegovy so much more expensive than Semasize?
You are paying for the originator brand: its global trial program, device heritage and worldwide supply chain. The molecule itself is off-patent in India since March 2026, which is why DCGI-approved generics cost a fraction of the imported price.
Ready to take the next step?
Take the free 2-minute eligibility assessment. A doctor reviews it before anything is prescribed — no obligation.
This article is for general educational purposes and is not a substitute for personalised medical advice. GLP-1 medications are prescription-only and not suitable for everyone. Always consult a qualified doctor before starting, changing, or stopping any treatment.
